Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Who's Camille Lee? Was she connected to Anavex or WSU?
For 2018, the statement read that review of out-licensing would be ongoing, that means Anavex would continue reviewing out-licensing opportunities. That doesn't mean that review of out-licensing opportunities cannot occur or has not occurred before 2018.
You say Anavex is done with MS. Then how come Anavex, just a couple weeks ago, was talking up 2-73 and MS at a conference? It's not like Anavex just within that last couple of weeks found out 2-73 flopped in Biogen's testing and Biogen is no longer interested. Biogen got their hands on 2-73 a year ago.
So, assuming Biogen failed to validate Wayne State's results, somehow that prompted Missling to go on an AVXL spending spree and mention out-licensing for the first time ever?
MS w/Biogen dead and buried? Not so fast. Possibly no mention b/c Biogen isn't working on preclinical testing anymore. That is probably wrapped up. Now, possible out-licensing talks between Anavex and Biogen, hence why on slide 22 at bottom Anavex mentions "out-licensing" for first time ever. What could have prompted that? Perhaps someone (Biogen) is interested in Anavex's goods? If out-licensing for MS goes forward, development for that indication would appear on Biogen's Pipeline Overview, not Anavex's
I think so
2-73 has shown improvement in mood and insomnia clinically for AD patients. Reduction in insomnia, agitation, and depression, which are all typical w/Alzheimers and very disruptive.
Well, the Melbourne rotary club McFarlane spoke at last month was a packed house. Lots of interest down under in what he had to say. I wonder why? Has word been getting around locally about the 25 patients still enrolled in the trial?
I really hope he doesn't pay any attention to social media and just focuses on the shareholders interests, as he's been doing.
The problem is that the patients enrolling in trial most likely have been on donepezil for some time, probably years. After 3-12 months, donepezil has "shot its wad" so to speak. In the mice preclinical trial, synergy was observed. The mice went on donepezil FOR THE FIRST TIME at the same time they were put on 2-73. However, in the clinical trial, the 25 patients on donepezil probably weren't just starting it for the first time at the start of the trial. Maybe that is why in the clinical trial synergy was not observed? Also, I do not think the dose of 2-73 and donepezil given in the preclinical trial was equivalent to the doses given in the clinical trial.
Nothing happens fast with Anavex, or frankly with most other biotechs. Things always wind up taking much longer than expected. Just look at the track record of Anavex.
Assuming that, which I have no idea, doesn't screening them take a lot of time? Remember how long it took to get all 32 Ph 2 Alzheimers patients enrolled. It took from Dec of 2014 all the way through Sept of 2015. 10 months!
Finally. I had assumed Anavex was on this before now but I guess not. Better late than never I suppose, but given the slow pace of Anavex, and biotech trials in general, I don't see final readouts for this trial until well into next year.
Here's a Stock Gumshoe write up from 3 years ago which reviewed another Casey Research Extraordinary Technology pump piece. That Casey article was pumping Prana, which had an Alzheimers drug in trial. That trial didn't live up to Casey's hype.
https://www.stockgumshoe.com/reviews/casey-extraordinary-technology/medicines-604-billion-memory-miracle-stock-teased-by-casey-extraordinary-technology/
Huh, I had a resistance line drawn at $4.48 on my chart, which is exactly where AVXL bounced off of today. I predict the stock will trade sideways in the $3.63 to $4.48 range.
Ah yeah, the Stock Gumshoe guy said most likely end game for AVXL for Alzheimers is failure and that it's a longshot, so I don't see why people would buying after reading his write up.
More like trying to cajole impatient investors not to bail rather than a signal of some spectacular upcoming news, If investors assume the latter I'm afraid they may be disappointed. I wouldn't read too much into it
Arrows every which way but the predominant direction is headed downward? 3.65 bottom gap fill likely is my interpretation from your posts.
The push up to 4.10 this past Monday was due to Missling buying shares last Friday. People interpreted that as a signal of good news to come this September. Do you think his expected buying another 750 shares today will also result in a price bump this coming Monday? You haven't really addressed that
You seriously subscribe to PubMed? I literally do not know anyone that does. Average Joe retail investors don't subscribe to PubMed. Are you a scientist/PhD, MD, or worker in the pharmaceutical industry? If PhD, what is your field?
You failed to answer my very pertinent and important question. Did you age adjust the Anavex Ph 2A group with the placebo group? Anavex did this, as they state on slide 30. It would be improper not to first do age adjustement before doing any sort of comparison. If you read both articles, you'd know why age adjustment is so vitally important before doing any sort of comparison. In fact, the conclusion to one of the slide 30 referenced articles, is that age has a big influence of rate of cognitive decline as assessed by MMSE and ADAS Cog.
The article you used and wrote the link for, was the study done in that article conducted by the AD Coop Study Group? On slide 30, Anavex mentions they used the data gathered by that group to do their comparison. The other article listed on slide 30, which you did not reference in any of your posts, makes mention of the AD Coop Study Group. Again, the abstract you linked to makes no mention of the AD Study Coop Group. Does the full text of that article cite that group?
So, how is it you have gained access to the full text? You just happen to subscribe to PubMed?
Reference slide 30 from CTAD 2016 presentation. Here is text appearing below the MMSE graph:
I followed that link and it led me to the abstract of a PubMed article. To access the full text would cost me $35. Did you get access somehow to the full text? The abstract contains no data points, so I'm still at a loss where you got data points from, unless you paid for that full article.
Give me a link to that source of only a 2 point drop in MMSE for placebo for mild to moderate patients over 57 weeks. Make sure they're mild to moderate patients. A two point drop is as low as it gets of a drop for placebos. I'm finding some graphs showing a 6 point drop. The historical placebos Anavex cited from Australia had a bigger drop. There are charts that show only a 2 point drop over two years for placebo, but only citing those is cherry picking. Do you have a problem with Anavex's historical control group that they used to compare their results to?
You ignore that the Anavex trial was A PHASE 2A trial. Do you know the diff btw Ph 2A and Ph 2B or Ph 3? The Anavex trial had 2/3'rds the patients on only 10, 20, and 30mg dosing. Optimal generally tolerated dose is prolly 40 or 50mg. The 10 mg patients weren't even on a dose that was at all therapeutic. The first five weeks of the 57 weeks included a 12 day washout period
You ignore the error bars. Talk to a statistician to learn how to interpret the results.
Why are you so obsessed w/a stock you are so extremely skeptical of? There are thousands of other stocks w/already proven products from which you may invest
Why aren't/weren't you so critical of another Alzheimer's stock you own? Its stock perfornance, market cap, recent management history, and clinical trial results all are worse than Anavex's.
Did you have a change of heart and dump it after its most recent P&D, or are you still in it? Do you now have a position (trading, investing, or shorting) in AVXL?
From your vast, comprehensive knowledge of prior Alzheimers trials to date, do you recall any trials where participants unanimously requested to be kept on the drug beyond the end of the trial? The Anavex 2-73 Ph 2A participants made such a request not once, but twice. Anavex complied with both requests, extending the trial from 6 mos to 1 year initially, and then granting a 2 yr extension to the formal Ph 2A trial. Those extensions were not planned by Anavex, they were accommodations to patient requests.
He doesn't care about traders of AVXL. He has other more important things on his mind right now. If he released some news at AAIC, good, bad, or neither, the stock would be in 2's or 3's right now.
Do you prefer to use charts with a weekly frequency and which indicator did you use to plot those channel lines?
If he's that accomplished and respected, he prolly wouldn't get on board unless he saw significant potential
Alzheimers patients have disrupted sleep often. Of the 8 out of 32 in the Anavex trial that had insomnia, all 8 had resolution of their insomnia during the trial. Impressive, and sleep is important for Alzheimers patients trying to stabilize. Might 2-73 help insomnia in the general population as well?
No abstract? Link?
wait, those drop outs were for both Ph 2A Part A (5 weeks) AND Ph 2A Part B (52 weeks). That's 57 weeeks combined, not 54.
It's a shame those patients that were grade 1 and 2 dizzy, lethargic, and/or disoriented dropped out so early. Assuming their symptoms were due to 2-73 and not something else (Alzheimers itself, another disease, old age, etc), those symptoms may have been only transient or could have resolved if Anavex had adjusted their dose, which is acceptable in an adaptive trial. Adding patients to an adaptive trial while it is in progress is also acceptable, but I don't think Anavex has done that.
Ahh, was that the old dude that spoke with a central or eastern european accent and his granddaughter was college aged with long brown hair?
$50/month? Oh I doubt that very much, at least not that cheap in the USA. My rx for just 1 tiny bottle/month of antihistamine eye drops is $200 cash price. Missling is a businessman first and foremost, not a humanitarian. His job has one goal: maximize profits for shareholders by any means. In fact, that is his legal fiduciary responsibility. If he isn't doing that, when he otherwise could be, then shareholders can sue him and they would win. Even if Missling doesn't want to be greedy, shareholders will demand that he is and drive the hardest bargains possible.
Will NTRP rise end of week? Its fallen from $10 down to $6.75 in a week on low volume! Damnn. Though it can rise just as fast.
You spoke too soon :( Cmon NTRP, what's the deal? You've got AAIC next week, lets see a run